Revenues

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.

Revenues were as follows (in millions):

	Three months ended June 30,
	2022						2021
	U.S.		ROW		Total		U.S.		ROW		Total
ENBREL	$	1,036	$	15	$	1,051	$	1,113	$	31	$	1,144
Prolia	611		311		922		538		276		814
Otezla	487		107		594		423		111		534
XGEVA	391		142		533		355		133		488
Aranesp	132		225		357		135		232		367
Neulasta	263		47		310		434		52		486
Repatha	154		171		325		143		143		286
KYPROLIS	213		104		317		190		90		280
Nplate	156		128		284		136		109		245
Other products	1,003		585		1,588		907		563		1,470
Total product sales(1)	$	4,446	$	1,835	6,281		$	4,374	$	1,740	6,114
Other revenues					313						412
Total revenues					$	6,594					$	6,526
	Six months ended June 30,
	2022						2021
	U.S.		ROW		Total		U.S.		ROW		Total
ENBREL	$	1,879	$	34	$	1,913	$	2,007	$	61	$	2,068
Prolia	1,193		581		1,774		1,039		533		1,572
Otezla	837		208		1,045		789		221		1,010
XGEVA	759		276		1,035		689		267		956
Aranesp	269		446		715		260		462		722
Neulasta	567		91		658		855		113		968
Repatha	319		335		654		282		290		572
KYPROLIS	409		195		604		349		182		531
Nplate	312		238		550		248		224		472
Other products	1,939		1,125		3,064		1,759		1,076		2,835
Total product sales(1)	$	8,483	$	3,529	12,012		$	8,277	$	3,429	11,706
Other revenues					820						721
Total revenues					$	12,832					$	12,427

____________

(1)    Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2022 and 2021.